Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis

Pharmacogenomics Journal

Volumn 17, Issue 1, 2017, Pages 84-91

  Clarelli, F ^a   Liberatore, G ^a   Sorosina, M ^a   Osiceanu, A M ^a   Esposito, F ^a   Mascia, E ^a   Santoro, S ^a   Pavan, G ^a   Colombo, B ^a   Moiola, L ^a   Martinelli, V ^a   Comi, G ^a   Martinelli Boneschi, F ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLUK2 KAINATE RECEPTOR; IMMUNOLOGIC FACTOR; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 3; NERVE CELL ADHESION MOLECULE; NINJ2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GRIK2 GENE; GRM3 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NINJ2 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETIC TESTING; QUANTITATIVE TRAIT LOCUS; TBXAS1 GENE; TREATMENT RESPONSE; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; ITALY; META ANALYSIS; MIDDLE AGED; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHENOTYPE; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES, NEURONAL; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHARMACOGENETICS; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; RECEPTORS, KAINIC ACID; RECEPTORS, METABOTROPIC GLUTAMATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84949570854     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.85     Document Type: Article

References (39)

1. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700-722
2. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-532
3. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI study group and the IFNB multiple sclerosis study group. Neurology 1993; 43: 662-667
4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294
5. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504
6. Río J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009; 5: 553-560
7. Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol 2014; 27: 246-259
8. Mahurkar S, Suppiah V, O'Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature. Autoimmun Rev 2014; 39: 178-186
9. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344
10. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972-978
11. Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T et al. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol 2015; 78: 115-127
12. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231
13. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FB et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127
14. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846
15. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
16. Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013; 19: 605-612
17. International Multiple Sclerosis Genetics Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 10: 214-219
18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
19. Li Y, Willer CJ, Scheet P, Ding J, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34: 816-834
20. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955-959
21. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP et al. Locus Zoom: Regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336-2337
22. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM et al. A versatile gene-based test for genome-wide association studies. Am J Hum Genet 2010; 87: 139-145
23. Elbers CC, van Eijk KR, Franke L, Mulder F, van der Schouw YT, Wijmenga C et al. Using genome-wide pathway analysis to unravel the etiology of complex diseases. Genet Epidemiol 2009; 33: 419-431
24. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007; 23: 257-258
25. Shabalin AA. Matrix eQTL: Ultra fast eQTL analysis via large matrix operations. Bioinformatics 2012; 10: 1353-1358
26. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249
27. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31: 3812-3814
28. Hecker M, Hartmann C, Kandulski O, Paap BK, Koczan D, Thiesen HJ et al. Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood. Mol Neurobiol 2013; 48: 737-756
29. Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H. Interferon-beta-1binduced short-and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 2013; 13: 443-451
30. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon β in multiple sclerosis. Eur J Neurol 2009; 16: 1202-1209
31. Romeo M. Rio Score and Modified Rio Score validation in an Italian cohort of relapsing-remitting multiple sclerosis patients (abstract P549). Presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 10-13 October 2012
32. Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-293
33. Wu C, MacLeod I, Su AI. BioGPS and MyGene.info: organizing online, gene-entric information. Nucl Acids Res 2013; 41: 561-565
34. Araki T, Milbrandt J. Ninjurin2, a novel homophilic adhesion molecule, is expressed in mature sensory and enteric neurons and promotes neurite outgrowth. J Neurosci 2000; 20: 187-195
35. Dimou L, Schnell L, Montani L, Duncan C, Simonen M, Schneider R et al. Nogo-Adeficient mice reveal strain-dependent differences in axonal regeneration. J Neurosci 2006; 26: 5591-5603
36. Ifergan I, Kebir H, Terouz S, Alvarez JI, Lécuyer MA, Gendron S et al. Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. Ann Neurol 2011; 70: 751-763
37. Hata M, Takahara S, Tsuzaki H, Ishii Y, Nakata K, Akagawa KS et al. Expression of Th2-skewed pathology mediators in monocyte-derived type 2 of dendritic cells (DC2). Immunol Lett 2009; 126: 29-36
38. Kabashima K, Murata T, Tanaka H, Matsuoka T, Sakata D, Yoshida N et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol 2003; 4: 694-701
39. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z et al. Foxp3+CD25 +CD4+natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27